

A new, phenotypically distinct subpopulation of Regulatory Killer T ex-Th17 cells expressing CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi}ROR^{low}IL-17^{low}

Maria S. Sayapina

Corresponding author: Maria S. Sayapina maria.sayapina@mail.ru

**Laboratory of Experimental Immunology, Immunology Frontier Research Center, Osaka
University, Osaka 565-0871, Japan**

Author Approval The author has seen and approved the manuscript

Th17 and regulatory T (Treg) cells are integral in maintaining immune homeostasis and Th17–Treg imbalance is associated with inflammatory immunosuppression in cancer. Here it is shown that in addition to ROR⁺Foxp3⁺ cells eTreg cells are a source of ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} (Regulatory Killer T – RKT) cells while the latest are much more suppressive. Moreover, we have identified a set of key cytokines that favor the generation and expansion ex-Th17 Foxp3^{low} cells. These findings should accelerate efforts to define the function of this new subset of Treg cells in the immune response to cancer.

Key words: Regulatory Killer T ex-Th17 cells, eTregs, CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi}ROR^{low}IL-17^{low} cells.

Introduction

Treg cells consist of functionally diverse subsets of immune suppressive T cells that play a crucial role in the modulation of immune responses and the reduction of deleterious immune activation [1, 2]. Treg cells may participate in the progression of cancer, especially with regard to the ability of Treg cells to promote the development of tumors [3]. It was described that the levels of intratumoral Treg cells correlating with better or worse outcomes depending on the tumor type [4, 5]. Recent studies indicate that human ovarian cancer cell line SKOV-3 could convert, in the presence of IL-2, Treg into Th17 cells. These results support the ability of the tumor microenvironment to regulate and expand IL-17-producing T-helper (Th17) cells. Similar results were obtained upon stimulation of CD4⁺ T cells in the absence of tumors but in the presence of IL-1 β /IL-6 and IL-2 [6]. Cytokine profile analysis revealed that ovarian tumor cells, tumor-derived fibroblasts, and antigenpresenting cells (APCs) secrete IL-1 β /IL-6 [7]. IL-1 β is a potent inducer of Th17 cell differentiation and expansion, whereas IL-6 is capable of expanding memory Th17 cells [8]. Gene profile analysis revealed that SMAD 6 and HDAC 11 are

hyperexpressed in ovarian cancer cell line SKOV-3 [9]. In its turn Smad6 is transcriptionally induced by the antiinflammatory cytokine TGF- β . On the one hand, the importance of the concentration of TGF- β was illustrated in selectively regulating Treg and Th17 development. Low concentrations of TGF- β favor Th17 differentiation by enhancing IL-23 receptor (IL-23R) expression, while high concentrations promote Treg differentiation by inhibit IL-23R up-regulation [10]. On the other hand, it was also described that ovarian tumor cells secreted a high amount of latent TGF- β (inactive form), but the level of active form of TGF- β was very low (≤ 30 pg/ml) or undetectable because of its short half-life [8, 11]. Importantly, most of all types of tumors secrete high amount of TGF- β . Whereas overexpression of HDAC11 was associated with inhibition of expression of the gene encoding IL-10 and higher IL-12 mRNA expression [12]. IL-12 and IL-23 shared the same IL-12R β 1 receptor subunit and are characterized by overlapping effects on target cells. As shown before, IL-23 stimulation is not only crucial for attaining full effector function but also necessary for double expression of IL-17A and IFN- γ , induction of T-bet and subsequent deviation toward IFN- γ production [13]. Here, it was provided an insightful mechanism by which ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} cells are generated from eTreg cells and regulated by cytokines that favor the generation and expansion exTh17Foxp3^{low} cells.

Results

I conducted 3 experiments aimed at deriving eTreg cells using BALB/c mice (1st time) and Foxp3-GFP-DTR (2 times), CD4⁺CD25⁺FOXP3^{DTR-GFP} cells were isolated from lymph nodes and spleen by flow cytometry cell sorting to high purity and stimulated with anti-CD3/CD28 coated Dynobeads and IL-2 (Fig. 1). FACS analyses of the isolated population was at day 3 after stimulation. As shown in Figure 2, ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} cells were clearly detectable in populations from the purified CD4⁺CD25⁺ T-cell fractions after in vitro expansion. Staining with anti-IL-17 antibody revealed that ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} cells secreted low level of IL-17, although ROR⁺FOXP3⁺ T cells produced high level of IL-17. Further experiments revealed that freshly isolated CD4^{low}CD25^{hi}T cells were strongly positive for CD49b and Foxp3 molecules and weakly positive for ROR (Fig. 3).




Figure 1. Sorting strategy and the purities of resultant population CD4+CD25+Foxp3+T cells.






Figure 2. CD4^{low} T cells express Foxp3 and CD49b.

So I am the first who describe this subpopulation of ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} cells.






Figure 3. CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} cells express low level of IL-17 and ROR.

We also sought to determine the role of key cytokines, as discussed earlier, in the generation and expansion of exTh17Foxp3^{low} cells.

In the next stage we tested the effects of IL-12, IL-1 β , IL-6, IL-23 on exTh17Foxp3^{low} differentiation and expansion by using Treg cells from Foxp3^{DTR-GFP} mouse. IL-2-containing medium provided a baseline for comparison. Analysis of ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi}

cells revealed that IL-23 plays a more prominent role in differentiation and expansion of exTh17 Foxp3^{low} cells than do IL-12 and IL-1 β . By contrast, IL-6 stimulated IL-17-producing ROR+Foxp3+T suppressive cells.

Discussion

In this work, we have described the new subpopulation of ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} cells. Importantly, our data demonstrate the differentiation of eTreg cells to ROR+Foxp3+ cells and exTh17 RKT cells. Bryl et al. have previously reported population of peripheral blood T cells with reduced CD4 and high CD25 expression (CD4^{low}CD25^{high}), that are able to non-specifically suppress the proliferation of autologous, previously polyclonally activated CD4+lymphocytes and to kill them by direct contact. CD4^{low}CD25^{high} T cells expressed significant amounts of both intracellular perforin and granzyme B. At the same time common NK/NKT antigens, including: CD16, CD56, CD94, CD158b, CD161 and invariant NKT (iNKT), - were not present on CD4^{low} T cells [14].

Also using whole-genome microarray data sets of the Immunological Genome Project, it was demonstrated a closer transcriptional relationship between NK cells and T cells than between any other leukocytes, distinguished by their shared expression of genes encoding molecules with similar signaling functions, including NT cells and Treg [15]. In terms of common expression of Zap70 and Prscq and potential expression of perforin and granzyme B we concluded that the definition of a CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} cells phenotype is enough to unambiguously detect and study the regulatory function of new subpopulation called Regulatory Killer T – RKT cells which fulfils the current phenotypic criteria identifying the exTh17 RKT cells by simultaneously expressing low amounts of ROR and IL-17A.

Thus, the relative concentration of IL-2, IL-12, IL-1 β and IL-23 in the tumor microenvironment may be a critical factor for the generation of exTh17 RKT that will be converted into INF- γ -producing exTh17Foxp3^{low} (exTh17/Th1) cells. Based on these findings, it was predicted that cytokine milieu (low amounts of TGF- β and high amounts of IL-2, IL-12, IL-1 β and IL-23) in cancer favors the generation and expansion of exTh17Foxp3^{low} cells, although further studies are needed to validate this concept.

In terms of several types of tumors secrete some cytokines, for example colorectal cancer express high level of IL-23, ovarian cancer – IL-12 (I am planning to prove it) the combination of IL-2, IL-12, IL-1 β and IL-23 in different ways enhanced the differentiation of exTh17Foxp3^{low} (exTh17/Th1) cells from eTreg cells while retaining their ability to expand ROR+Foxp3+ T cells. IL-23 as a critical factor driving exTh17Foxp3^{low} cell expansion. Our

findings clearly support the emerging concept that tumor environmental factors drive the generation and expansion of exTh17Foxp3^{low} cells. This knowledge should accelerate efforts to describe the new subpopulation ex-Th17 CD4^{low}CD25^{hi}CD49^{hi}Foxp3^{hi} (RKT) cells in more detail and create several drugs for several immunogenic types of tumors (melanoma, ovarian cancer, renal cancer, colorectal cancer) on the basis of IL-2, IL-12, IL-1 β and IL-23 that will be delivered locoregionally (intraperitoneally, intrahepatic artery etc) to decrease systemic toxicity.

Methods

Cell culture

CD4⁺Tcells that were isolated from FDG mouse by negative selection with mouse CD4⁺Isolation Kit and were further separated into CD4⁺CD25⁺FOXP3^{DTR-GFP}+eTregcells using a FACS ARIA II instrument. Sorted 1,2x10⁵ eTreg cells were cultured in the presence of anti-CD3- and anti-CD28-coated (2,5 ml) Dynabeads and IL-2 (100U/ml). In some cultures IL-12 (30ng/l), IL-1 β (30ng/ml), IL-6 (30ng/ml), IL-23 (30 ng/ml) were added. Cells were analysed with an FACS Canto instrument 3 days later.

Cells were cultured in culture medium (RPMI-1640 supplemented with 100 U/mL penicillin, 100 g/mL streptomycin, 5 mM 2-mercaptoethanol, 0.05% and 10% fetal bovine serum [FBS]) at 37°C, and 5% CO₂, in 96-well round-bottom plates (Greiner, Frickenhausen, Germany).

Antibodies and reagents

Allophycocyanin (APC)- and Cy7- conjugated anti-CD4 (RM 4-5) mAb, phycoerythrin (PE) – and Cy7-conjugated anti-CD4(RM 4-5) mAb, peridinin chlorophyll protein complex (PerCP)- and Cy5.5-conjugated anti-CD25 (PC-61) mAb, phycoerythrin (PE) anti-ROR (Q31-378) mAb were purchased from Bioscience. Brilliant Violet 421(BV421) – conjugated anti-IL-17 (TC-11-18H 10.1) mAb, Alexa Fluor 647-conjugated anti-CD49b (DX5), LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit were purchased from Biolegend. Recombinant murine IL-6, IL-12, IL-23, IL-1 β were purchased from Sarstedt and Bioscience.

All results were received by the author personally in 01.2018 and reported on a scientific club in the laboratory on January 29, 2013, and this was the continuation of the author's dissertation work [16].

ACKNOWLEDGMENTS. I thank Professor Shimon Sakaguchi for his encouragement and support.


References

1. Zhang et al. Analysis of CD81 Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment *Cellular & Molecular Immunology* 2015 12, 580–591
2. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. *Cancer Res* 2012; 72: 2162–2171.
3. Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ et al. Depletion of CD41CD251 regulatory T cells promotes a tumorspecific immune response in pancreas cancer-bearing mice. *Ann Surg Oncol* 2006; 13: 1252–1258.
4. Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z et al. Prognostic significance of FOXP31 tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. *Breast Cancer Res* 2014; 16: 432.
5. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al. Tumor-infiltrating FOXP31 T regulatory cells show strong prognostic significance in colorectal cancer. *J Clin Oncol* 2009; 27: 186–192.
6. Leveque et al. Interleukin 2-mediated Conversion of Ovarian Cancer-associated CD4+ Regulatory T Cells Into Proinflammatory Interleukin 17-producing Helper T Cells. *J Immunother* 2009;32:101–108
7. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. *Cancer Res.* 2005;65:10794–10800.
8. Miyahara et al. Generation and regulation of human CD4+IL-17-producing T cells in ovarian cancer. *PNAS*; October 7, 2008; vol. 105, no. 40; 15505–15510
9. http://amp.pharm.mssm.edu/Harmonizome/gene_set/SKOV3/CCLE+Cell+Line+Gene+Expression+Profiles
10. Zhou et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. *Nature*. 2008 May 8;453(7192):236-40.
11. Carr TM, Adair SJ, Fink MJ, Hogan KT (2008) Immunological profiling of a panel of human ovarian cancer cell lines. *Cancer Immunol Immunother* 57:31–42.

12. Villagra et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. NATURE IMMUNOLOGY. VOLUME 10 NUMBER 1 JANUARY 2009; pp. 92-100
13. Hirota et al. Fate mapping of IL-17-producing T cells in inflammatory responses. nature immunology VOLUME 12 NUMBER 3 MARCH 2011 pp. 255-260
14. Bryl et al. Human CD4^{low} CD25^{high} regulatory T cells indiscriminately kill autologous activated T cells. Immunology 2009, 128, e287–e295
15. Bezman et al. Molecular definition of the identity and activation of natural killer cells. Nature Immunology VOLUME 13 NUMBER 10 OCTOBER 2012 1000-1009
16. <http://www.ronc.ru/node/2246>

BOB

II.3



II.4p



II.5



II.4i




II.4b



H1000R

II. 3



II. 14



II. 4



II. 17


II. 13







II. 23



FORP3





0.01



0.02



0.03



0.04



0.05



	Key statistics	
	mean	std dev
0.01	0.01	0.01
0.02	0.01	0.01
0.03	0.01	0.01
0.04	0.01	0.01
0.05	0.01	0.01

H.2



H.11



H.10



H.19



H.6



H.17

POST3

29

